Improving Glycemic Control on GMS: A Quality Improvement Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Brigham and Women's Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Novo Nordisk
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00271700
First received: December 30, 2005
Last updated: May 3, 2010
Last verified: May 2010

December 30, 2005
May 3, 2010
May 2010
March 2011   (final data collection date for primary outcome measure)
  • - Point-of-care testing glucose values (percent of routine glucose readings between 60 and 180 mg/dL)
  • - Lab glucose values (percent of routine glucose readings between 60 and 180 mg/dL)
Same as current
Complete list of historical versions of study NCT00271700 on ClinicalTrials.gov Archive Site
- Quality of insulin orders using explicit criteria
Same as current
Not Provided
Not Provided
 
Improving Glycemic Control on GMS: A Quality Improvement Study
Improving Glycemic Control on GMS: A Quality Improvement Study

This study will examine whether new processes and technologies for monitoring diabetic patients' insulin levels improves patient care at Brigham and Women's Hospital.

This study will examine whether new processed and technologies for monitoring diabetic patients' insulin levels improves patient care. Patients at Brigham and Women's Hospital (BWH), staying on the General Medicine Service, who have Type 2 diabetes and who are not on IV insulin can participate in this study. Physicians and nurses will be taught new rules to care for diabetic patients, while in the hospital. Also, the BWH computer system will be updated to include these new rules for administering insulin. Patients who participate in the study will be randomly placed into one of two groups: one group that will be cared for by physicians and nurses who have learned these new rules for administering insulin; or the second group, who will receive diabetes care at BWH before the new rules were adopted. The study will last approximately 1 year.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Diabetes Mellitus
Behavioral: Order Set, Education, Feedback
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
1100
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects will include all type 2 diabetic patients on the General Medicine Service (GMS) of Brigham and Women's Hospital (BWH) who do not have an indication for IV insulin.

Exclusion Criteria:

  • Type 2 diabetic patients on the General Medicine Service (GMS) of Brigham and Women's Hospital (BWH) who have an indication for IV insulin.
Both
18 Years and older
No
Contact: Jeffrey L. Schnipper, MD, MPH 617-732-6201 jschnipper@partners.org
United States
 
NCT00271700
2005-P-001880/1, 2005-P-001880/1
Not Provided
Jeffrey L. Schnipper, MD, MPH, Brigham & Women's Hospital
Brigham and Women's Hospital
Novo Nordisk
Principal Investigator: Jeffrey L Schnipper, MD, MPH Brigham and Women's Hospital
Brigham and Women's Hospital
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP